Search Results - "Gimpelewicz, C."

Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure by Beldhuis, I. E., ter Maaten, J. M., Figarska, S. M., Damman, K., Pang, P. S., Greenberg, B., Davison, B. A., Cotter, G., Severin, T., Gimpelewicz, C., Felker, G. M., Filippatos, G., Teerlink, J. R., Metra, M., Voors, A. A.

“…Background We aimed to study whether improvement in renal function by serelaxin in patients who were hospitalized for acute heart failure (HF) might explain…”
Get full text

Renal Dysfunction Is a Strong and Independent Risk Factor for Mortality and Cardiovascular Complications in Renal Transplantation by Fellström, B., Jardine, A. G., Soveri, I., Cole, E., Neumayer, H.‐H., Maes, B., Gimpelewicz, C., Holdaas, H.

“…Renal transplant recipients (RTR) have shortened life expectancy, primarily due to premature cardiovascular disease (CVD). Traditional CVD risk factors are…”
Get full text

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation by Holdaas, Hallvard, Fellström, Bengt, Jardine, Alan G., Nyberg, Gudrun, Grönhagen-Riska, Carola, Madsen, Sören, Neumayer, Hans-Hellmut, Cole, Edward, Maes, Bart, Ambühl, Patrice, Logan, John O., Staffler, Beatrix, Gimpelewicz, Claudio

“…Background. Renal transplant recipients have a significantly reduced life expectancy, largely due to premature cardiovascular disease. The aim of the current…”
Get full text

Fluvastatin treatment is not associated with an increased incidence of cancer by Stein, E A, Corsini, A, Gimpelewicz, C R, Bortolini, M, Gil, M

“…Concerns regarding a potential link between statin treatment and increased risk of cancer were raised following the increased cancer incidence observed in…”
Get more information

Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation : Experience from the assessment of lescol in renal transplantation trial by FELLSTRÖM, Bengt, JARDINE, Alan G, SOVERI, Inga, COLE, Edward, GRBNHAGEN-RISKA, Carola, NEUMAYER, Hans H, MAES, Bart, GIMPELEWICZ, Claudio, HOLDAAS, Hallvard

“…Renal-transplant recipients have shortened life expectancy primarily because of premature cardiovascular disease. Traditional and nontraditional risk factors…”
Get full text

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure by Beldhuis, I E, Damman, K, Pang, P S, Greenberg, B, Davison, B A, Cotter, G, Gimpelewicz, C, Felker, G M, Filippatos, G, Teerlink, J R, Metra, M, Voors, A A, Ter Maaten, J M

“…Heart failure (HF) guidelines recommend initiation and optimization of guideline directed medical therapy (GDMT), including mineralocorticoid receptor…”
Get full text

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy by Shen, Li, Ramires, Felix, Martinez, Felipe, Bodanese, Luiz Carlos, Echeverría, Luis Eduardo, Gómez, Efraín A, Abraham, William T, Dickstein, Kenneth, Køber, Lars, Packer, Milton, Rouleau, Jean L, Solomon, Scott D, Swedberg, Karl, Zile, Michael R, Jhund, Pardeep S, Gimpelewicz, Claudio R, McMurray, John J V

“…Chagas' disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart…”
Get full text

The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial by Janwanishstaporn, S., Feng, S., Teerlink, J.R., Metra, M., Cotter, G., Davidson, B.A., Felker, M., Filippatos, G., Pang, P.S., Ponikowski, P., Severin, T., Gimpelewicz, C., Sama, I.E., Voors, A.A., Greenberg, B.

“…Although left ventricular ejection fraction (LVEF) is routinely used to categorize heart failure (HF) patients, whether this variable predicts outcomes across…”
Get full text

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial by Maggioni, Aldo P, Greene, Stephen J, Fonarow, Gregg C, Böhm, Michael, Zannad, Faiez, Solomon, Scott D, Lewis, Eldrin F, Baschiera, Fabio, Hua, Tsushung A, Gimpelewicz, Claudio R, Lesogor, Anastasia, Gheorghiade, Mihai

“…The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve…”
Get full text

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment by Cowie, Martin R., Filippatos, Gerasimos S., Alonso Garcia, Maria de los Angeles, Anker, Stefan D., Baczynska, Anna, Bloomfield, Daniel M., Borentain, Maria, Bruins Slot, Karsten, Cronin, Maureen, Doevendans, Pieter A., El‐Gazayerly, Amany, Gimpelewicz, Claudio, Honarpour, Narimon, Janmohamed, Salim, Janssen, Heidi, Kim, Albert M., Lautsch, Dominik, Laws, Ian, Lefkowitz, Martin, Lopez‐Sendon, Jose, Lyon, Alexander R., Malik, Fady I., McMurray, John J.V., Metra, Marco, Figueroa Perez, Santiago, Pfeffer, Marc A., Pocock, Stuart J., Ponikowski, Piotr, Prasad, Krishna, Richard‐Lordereau, Isabelle, Roessig, Lothar, Rosano, Giuseppe M.C., Sherman, Warren, Stough, Wendy Gattis, Swedberg, Karl, Tyl, Benoit, Zannad, Faiez, Boulton, Caroline, De Graeff, Pieter

“…Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart failure…”
Get full text

Renal transplant dysfunction—importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality by Soveri, Inga, Holdaas, Hallvard, Jardine, Alan, Gimpelewicz, Claudio, Staffler, Beatrix, Fellström, Bengt

“…Background. Renal transplant recipients (RTR) mainly die of premature cardiovascular disease. Traditional cardiovascular disease risk factors are prevalent in…”
Get full text

Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: A pooled analysis of thirty clinical trials by Winkler, Karl, MD, Ablethauser, Claudia B., PhD, Gimpelewicz, Claudio, MD, Bortolini, Michele, MD, Isaacsohn, Jonathan L., MD

“…Abstract Objective: This pooled analysis of 30 completed clinical trials assessed the efficacy and safety profile in reducing cardiovascular disease (CVD) risk…”
Get full text

NO DETRIMENTAL EFFECT ON RENAL FUNCTION DURING LONG-TERM USE OF FLUVASTATIN by Holdaas, H, Fellström, B, Jardine, A, Nyberg, G, Grönhagen-Riska, C, Madsen, S, Neumayer, H -H., Cole, E, Maes, B, Hartmann, A, Ambühl, P, Gimpelewicz, C, Staffler, B, Logan, J O.

Get full text

Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al by Ramires, Felix J.A., Martinez, Felipe, Gómez, Efraín A., Demacq, Caroline, Gimpelewicz, Claudio R., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Packer, Milton, McMurray, John J.V.

Get full text

Mo-P5:352 Risk reduction and safety of fluvastatin in patients with the metabolic syndrome by Winkler, K., Abletshauser, C., Gimpelewicz, C., Bortolini, M., Isaacsohn, J.

Get full text

W16-O-001 Fluvastatin additional benefit beyond LDL-C reduction: A comparison of cardiovascular events risk in patients with the same level of on treatment LDL by Bogaerts, K., Tsonaka, S., Rizopoulous, D., Lessafre, E., Gimpelewicz, C., Logan, J.O., Bortolini, M.

Get full text

W16-P-031 Fluvastatin safety profile in patients with low levels of ldl cholesterol in the Lescol® intervention prevention study by Lemos, P., Arampatzis, C.A., Goedhart, D., Gimpelewicz, C., Freudenreich, M., Logani, J.O., Bortolini, M., Serruys, P.

Get full text